WO2002072888A3 - Polymorphisms in the human cmoat gene and uses thereof - Google Patents

Polymorphisms in the human cmoat gene and uses thereof Download PDF

Info

Publication number
WO2002072888A3
WO2002072888A3 PCT/GB2002/000651 GB0200651W WO02072888A3 WO 2002072888 A3 WO2002072888 A3 WO 2002072888A3 GB 0200651 W GB0200651 W GB 0200651W WO 02072888 A3 WO02072888 A3 WO 02072888A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymorphisms
cmoat
gene
human
cmoat gene
Prior art date
Application number
PCT/GB2002/000651
Other languages
French (fr)
Other versions
WO2002072888A2 (en
Inventor
Carl John Cresswell
Adam Jeston Dudley
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Carl John Cresswell
Adam Jeston Dudley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0103990A external-priority patent/GB0103990D0/en
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Carl John Cresswell, Adam Jeston Dudley filed Critical Astrazeneca Ab
Priority to AU2002229979A priority Critical patent/AU2002229979A1/en
Priority to JP2002571938A priority patent/JP2004524846A/en
Priority to EP02711085A priority patent/EP1379688A2/en
Priority to US10/468,326 priority patent/US20050118579A1/en
Publication of WO2002072888A2 publication Critical patent/WO2002072888A2/en
Publication of WO2002072888A3 publication Critical patent/WO2002072888A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention relates to polymorphisms in the human cMOAT gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the cMOAT gene, and to the use of cMOAT polymorphism in treatment of diseases with cMOAT transportable drugs.
PCT/GB2002/000651 2001-02-17 2002-02-12 Polymorphisms in the human cmoat gene and uses thereof WO2002072888A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002229979A AU2002229979A1 (en) 2001-02-17 2002-02-12 Polymorphisms in the human cmoat gene and uses thereof
JP2002571938A JP2004524846A (en) 2001-02-17 2002-02-12 Chemical compound
EP02711085A EP1379688A2 (en) 2001-02-17 2002-02-12 Polymorphisms in the human cmoat gene and uses thereof
US10/468,326 US20050118579A1 (en) 2001-02-17 2002-02-12 Chemical compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0103990.8 2001-02-17
GB0103990A GB0103990D0 (en) 2001-02-17 2001-02-17 Chemical compounds
US27510601P 2001-03-13 2001-03-13
US60/275,106 2001-03-13

Publications (2)

Publication Number Publication Date
WO2002072888A2 WO2002072888A2 (en) 2002-09-19
WO2002072888A3 true WO2002072888A3 (en) 2003-11-13

Family

ID=26245726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/000651 WO2002072888A2 (en) 2001-02-17 2002-02-12 Polymorphisms in the human cmoat gene and uses thereof

Country Status (5)

Country Link
US (1) US20050118579A1 (en)
EP (1) EP1379688A2 (en)
JP (1) JP2004524846A (en)
AU (1) AU2002229979A1 (en)
WO (1) WO2002072888A2 (en)

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BUECHLER M ET AL: "CDNA CLONING OF THE HEPATOCYTE CANALICULAR ISOFORM OF THE MULTIDRUG RESISTANCE PROTEIN, CMRP, REVEALS A NOVEL CONJUGATE EXPORT PUMP DEFICIENT IN HYPERBILIRUBINEMIC MUTANT RATS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 25, CAA65259, 21 June 1996 (1996-06-21), pages 15091 - 15098, XP000606392, ISSN: 0021-9258 *
DATABASE EMBL [online] 11 June 2003 (2003-06-11), KEPPLER D.: "Multidrug resistance protein 2 (MRP2) (Homo sapiens)", XP002249641, Database accession no. CAB45309 *
DATABASE EMBL [online] 25 May 2001 (2001-05-25), KEPPLER D.: "Canalicular multidrug resistange protien (Homo sapiens)", XP002249642, Database accession no. CAA65259 *
DATABASE EMBL [online] 7 November 1996 (1996-11-07), TANIGUCHI K. ET AL.: "Canalicular multispecific organic anion transporter [Homo sapiens]", XP002249640, Database accession no. AAB39892 *
KERB R ET AL: "ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2.", PHARMACOGENOMICS. ENGLAND FEB 2001, vol. 2, no. 1, February 2001 (2001-02-01), pages 51 - 64, XP009014717, ISSN: 1462-2416 *
KOENIG JOERG ET AL: "Conjugate export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity, and MRP2-mediated drug resistance.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1461, no. 2, 6 December 1999 (1999-12-06), pages 377 - 394, XP002249636, ISSN: 0006-3002 *
PAULUSMA C C ET AL: "CONGENITAL JAUNIDICE IN RATS WITH A MUTATION IN A MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN GENE", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 271, 23 February 1996 (1996-02-23), pages 1126 - 1128, XP000606395, ISSN: 0036-8075 *
SCHEFFER GEORGE L ET AL: "Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies.", CANCER RESEARCH, vol. 60, no. 18, 15 September 2000 (2000-09-15), pages 5269 - 5277, XP002249637, ISSN: 0008-5472 *
TANIGUCHI KEN ET AL: "A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation.", CANCER RESEARCH, vol. 56, no. 18, 1996, pages 4124 - 4129, XP000607845, ISSN: 0008-5472 *
TOH S ET AL: "Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome.", AMERICAN JOURNAL OF HUMAN GENETICS. UNITED STATES MAR 1999, vol. 64, no. 3, March 1999 (1999-03-01), pages 739 - 746, XP002249635, ISSN: 0002-9297 *
TSUJII HIROYUKI ET AL: "Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome.", GASTROENTEROLOGY, vol. 117, no. 3, CAB45309, 1999, pages 653 - 660, XP009014900, ISSN: 0016-5085 *
WADA M ET AL: "Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome.", HUMAN MOLECULAR GENETICS. ENGLAND FEB 1998, vol. 7, no. 2, February 1998 (1998-02-01), pages 203 - 207, XP002249633, ISSN: 0964-6906 *

Also Published As

Publication number Publication date
EP1379688A2 (en) 2004-01-14
WO2002072888A2 (en) 2002-09-19
US20050118579A1 (en) 2005-06-02
AU2002229979A1 (en) 2002-09-24
JP2004524846A (en) 2004-08-19

Similar Documents

Publication Publication Date Title
WO2004006858A3 (en) Compounds, compositions, and methods employing same
AU2002255248A1 (en) Diagnosis, treatment and research of mental disorders
ZA200500882B (en) Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis of treatment or liver disorders and epithelial cancer
AU2003289888A1 (en) Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
WO2002076494A3 (en) USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS
EP1487446A4 (en) Bicyclic heterocycles for the treatment of diabetes and other diseases
EP1186672A3 (en) Polymorphisms in the human organic anion transporter C (OATP-C) gene
WO2004032850A3 (en) Uses of human zven antagonists
EP1422240A3 (en) Analogs of nociceptin
ZA200400313B (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine.
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
WO2003076472A3 (en) Neoplasm specific antibodies and uses thereof
WO2004094465A8 (en) Synthetic molecules that mimic chemokines
EP1199372A3 (en) Polymorphisms in the human P2X7 gene
WO2001059120A3 (en) Il-17 like molecules and uses thereof
WO2002072888A3 (en) Polymorphisms in the human cmoat gene and uses thereof
WO2004005351A3 (en) Neoplasm specific antibodies and uses thereof
WO2005101013A3 (en) Materials and methods for screening modulators of neural regneration
WO2004005540A3 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
EP1130122A3 (en) Methods for the diagnosis of polymorphisms in the human EP1-R gene
WO2003014391A3 (en) Method for the detection of a polymorphism in cpb2
EP1184465A3 (en) Method for diagnosing polymorphisms in human MCT-1 and drugs related to such polymorphisms
WO2002083944A3 (en) Chemical compounds for identification of slc10a2 gene polymorphisms
EP1741722A3 (en) Polymorphisms in the human P2X7 gene
WO2000006769A3 (en) Human ccr-2 gene polymorphisms

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002711085

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002571938

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002711085

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10468326

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002711085

Country of ref document: EP